0001104659-24-029417.txt : 20240229 0001104659-24-029417.hdr.sgml : 20240229 20240229164606 ACCESSION NUMBER: 0001104659-24-029417 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240229 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 24704623 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 8-K 1 tm247530d1_8k.htm FORM 8-K
false 0001649904 0001649904 2024-02-29 2024-02-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 29, 2024

 

RHYTHM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38223   46-2159271
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification Number)

 

222 Berkeley Street

12th Floor

Boston, MA 02116

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (857) 264-4280

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading
Symbol(s)		 Name of each exchange on which registered
Common Stock, $0.001 par value per share RYTM The Nasdaq Stock Market LLC (Nasdaq Global Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

As previously reported, on November 2, 2021, Rhythm Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement with Cowen and Company, LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), from time to time through TD Cowen acting as sales agent, having a maximum aggregate offering price of $100,000,000. The issuances and sales under the Sales Agreement were made pursuant to the Company’s registration statement on Form S-3 (File No. 333-270233) (the “Registration Statement”) filed with the Securities and Exchange Commission (the “SEC”) on March 2, 2023, and a prospectus supplement and base prospectus included in the Registration Statement (the “Base Prospectus”), each dated March 2, 2023 (together, the “Prior Prospectus”). As of February 29, 2024, the Company had offered and sold shares of Common Stock pursuant to the Sales Agreement for aggregate gross proceeds to the Company of approximately $50.0 million.

 

On February 29, 2024, the Company and TD Cowen entered into Amendment No. 1 to Sales Agreement (the “Amendment”) to increase the aggregate offering price of the shares of Common Stock that may be issued and sold pursuant to the Sales Agreement to $200,000,000 (excluding the aggregate offering price of shares of Common Stock issued and sold pursuant to the Sales Agreement prior to February 29, 2024). In connection with the Amendment, on February 29, 2024, the Company filed with the SEC a prospectus supplement, dated February 29, 2024, which, combined with the Base Prospectus (together, the “New Prospectus”), amended the Prior Prospectus in its entirety. The issuances and sales under the Sales Agreement, as amended by the Amendment, will be made pursuant to the Registration Statement and the New Prospectus.

 

The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the full text of such amendment, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K (the “Current Report”) and is incorporated herein by reference.

 

The legal opinion of Latham & Watkins LLP relating to the shares of Common Stock being sold pursuant to the Sales Agreement, as amended by the Amendment, is filed as Exhibit 5.1 to this Current Report.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Exhibit Description
1.1   Amendment No. 1 to Sales Agreement, dated as of February 29, 2024, between Rhythm Pharmaceuticals, Inc. and Cowen and Company, LLC.
5.1   Opinion of Latham & Watkins LLP.
23.1   Consent of Latham & Watkins LLP (included in Exhibit 5.1).
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RHYTHM PHARMACEUTICALS, INC.
     
Date: February 29, 2024 By: /s/ Hunter Smith                         
    Hunter Smith
    Chief Financial Officer

 

 

 

 

 

 

 EX-1.1 2 tm247530d1_ex1-1.htm EXHIBIT 1.1

 

Exhibit 1.1 

 

RHYTHM PHARMACEUTICALS, Inc.

 

Common Stock

 

AMENDMENT NO. 1 TO SALES AGREEMENT

 

February 29, 2024

 

Cowen and Company, LLC

599 Lexington Avenue

New York, NY 10022

 

Ladies and Gentlemen:

 

Reference is made to the Sales Agreement, dated November 2, 2021 (the “Agreement”), by and between Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“Cowen”). The Company and Cowen (collectively, the “Parties”) wish to amend the Agreement, pursuant to Section 15 of the Agreement, to increase the aggregate offering price under the Agreement (this “Amendment”). The Parties therefore hereby agree as follows:

 

1. On the date hereof, the Company has filed or will file a Prospectus Supplement relating to the offering of up to $200,000,000 of Common Stock (the “February 2024 ATM Prospectus Supplement”), to the base prospectus, dated March 2, 2023, contained in the registration statement on Form S-3 (Registration No. 333-270233). The February 2024 ATM Prospectus Supplement shall update and amend the prospectus supplement filed by the Company on March 2, 2023 relating to the Common Stock offered pursuant to the Agreement in its entirety.

 

2.Issuance and Sale of Shares. The first paragraph of Section 1 of the Agreement is hereby amended and restated in its entirety to read as follows:

 

‘The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through Cowen, acting as agent and/or principal, shares (the “Placement Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $200,000,000, excluding the aggregate offering price of Placement Shares issued and sold prior to February 29, 2024 pursuant to this Agreement. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this Section 1 on the number of shares of Common Stock issued and sold under this Agreement shall be the sole responsibility of the Company, and Cowen shall have no obligation in connection with such compliance. The issuance and sale of Common Stock through Cowen will be effected pursuant to the Registration Statement (as defined below) filed by the Company and after such Registration Statement has been declared effective by the Securities and Exchange Commission (the “Commission”), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement (as defined below) to issue the Common Stock.’

 

3.Agreement Heading. The reference to “$100,000,000” in the heading of the Agreement shall be removed and replaced with “$200,000,000”.
   
 4. Expenses. Clause (viii) of Section 7(g) of the Agreement is hereby amended and restated in its entirety to read as follows:

 

`(viii) the reasonable fees and disbursements of Cowen's counsel in an amount not to exceed $75,000.'

 

 

 

 

5.A new Section 20 as set forth below is hereby added to the Sales Agreement immediately following Section 19 thereof:

 

“20. Recognition of the U.S. Special Resolution Regimes.

 

(a) In the event that Cowen is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from Cowen of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

 

(b) In the event that Cowen is a Covered Entity and Cowen or a BHC Act Affiliate of Cowen becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against Cowen are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

 

(c) For purposes of this Section 20; (a) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k), (b) “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b), (c) “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable, and (d) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.”

 

6. For the avoidance of doubt, any reference to “Prospectus” in the Agreement shall be deemed to include the February 2024 ATM Prospectus Supplement.

 

7. Governing Law. THIS AMENDMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.

 

8. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

 

 

 

9. Agreement Remains in Effect. Except as provided herein, all provisions, terms and conditions of the Agreement shall remain in full force and effect. As amended hereby, the Agreement is ratified and confirmed in all respects.

 

Terms used herein but not otherwise defined are used herein as defined in the Agreement.

 

(Signature page follows)

 

 

 

 

If the foregoing correctly sets forth the understanding between the Company and Cowen, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and Cowen.

 

  Very truly yours,
   
  COWEN AND COMPANY, LLC
   
  By: /s/ Michael Murphy
  Name:  Michael Murphy
  Title:  Managing Director
   
  ACCEPTED as of the date
  first-above written:
   
  RHYTHM PHARMACEUTICALS, INC.
   
  By: /s/ Hunter Smith                                
  Name: Hunter Smith 
  Title: Chief Financial Officer 

 

 

 

 

 EX-5.1 3 tm247530d1_ex5-1.htm EXHIBIT 5.1

 

Exhibit 5.1

 

  200 Clarendon Street
  Boston, Massachusetts 02116
  Tel: +1.617.948.6000 Fax: +1.617.948.6001
  www.lw.com
FIRM / AFFILIATE OFFICES
  Austin Milan
  Beijing Munich
  Boston New York
  Brussels Orange County
  Century City Paris
  Chicago Riyadh
February 29, 2024 Dubai San Diego
  Düsseldorf San Francisco
  Frankfurt Seoul
  Hamburg Silicon Valley
  Hong Kong Singapore
  Houston Tel Aviv
  London Tokyo
  Los Angeles Washington, D.C.
Rhythm Pharmaceuticals, Inc. Madrid

222 Berkeley Street

12th Floor

Boston, Massachusetts 02116

 

Re:Registration Statement on Form S-3 (Registration No. 333-270233); Shares of Common Stock, $0.001 par value per share, having an aggregate offering price of up to $200.0 million

 

To the addressee set forth above:

 

We have acted as special counsel to Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the sale through Cowen and Company, LLC, as sales agent (the “Sales Agent”), from time to time by the Company of shares of common stock, $0.001 par value per share, having an aggregate offering price of up to $200.0 million (the “Shares”) pursuant to (i) a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 2, 2023 (Registration No. 333-270233) (the “Registration Statement”), (ii) a base prospectus dated March 2, 2023 (the “Base Prospectus”), (iii) a related prospectus supplement filed with the Commission on the date hereof pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the “Prospectus”), and (iv) that certain Sales Agreement, dated November 2, 2021, by and between the Company and the Sales Agent, as amended by Amendment No. 1 to the Sales Agreement, dated as of the date hereof (the “Sales Agreement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related Prospectus, other than as expressly stated herein with respect to the issue of the Shares.

 

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

 

 

 

February 29, 2024

Page 2

 

 

 

Subject to the foregoing and the other matters set forth herein, it is our opinion that, upon the completion of all Corporate Proceedings (as defined below) relating to the Shares, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, upon issuance, delivery and payment therefor in an amount not less than the par value thereof in accordance with the Corporate Proceedings and the terms of the Sales Agreement, the Shares to be issued and sold by the Company pursuant to the Sales Agreement will be duly authorized by all necessary corporate action of the Company and such Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that (i) the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL, (ii) upon the issuance of any of the Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its certificate of incorporation, and (iii) certain terms of the Shares to be issued by the Company from time to time will be authorized and approved by the board of directors of the Company or one or more committees thereof established by the board of directors of the Company with the authority to issue and sell Shares pursuant to the Sales Agreement in accordance with the DGCL, the Company’s certificate of incorporation, the by-laws of the Company and certain resolutions of the board of directors of the Company and one or more committees thereof (with such approvals referred to herein as the “Corporate Proceedings”) prior to issuance thereof.

 

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company’s Form 8-K dated February 29, 2024 and to the reference to our firm contained in the Registration Statement and in the Prospectus under the heading “Legal Matters.” In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

 Sincerely,
  
 /s/ Latham & Watkins LLP

 

 

 EX-101.SCH 4 rytm-20240229.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 rytm-20240229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 rytm-20240229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm247530d1_ex5-1img001.jpg GRAPHIC begin 644 tm247530d1_ex5-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 29, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 29, 2024
Entity File Number 001-38223
Entity Registrant Name RHYTHM PHARMACEUTICALS, INC.
Entity Central Index Key 0001649904
Entity Tax Identification Number 46-2159271
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 222 Berkeley Street
Entity Address, Address Line Two 12th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02116
City Area Code 857
Local Phone Number 264-4280
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol RYTM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rhythmtx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports rytm-20240229.xsd rytm-20240229_lab.xml rytm-20240229_pre.xml tm247530d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm247530d1_8k.htm": { "nsprefix": "rytm", "nsuri": "http://rhythmtx.com/20240229", "dts": { "schema": { "local": [ "rytm-20240229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rytm-20240229_lab.xml" ] }, "presentationLink": { "local": [ "rytm-20240229_pre.xml" ] }, "inline": { "local": [ "tm247530d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://rhythmtx.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247530d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247530d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://rhythmtx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001104659-24-029417-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-029417-xbrl.zip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end XML 18 tm247530d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001649904 2024-02-29 2024-02-29 iso4217:USD shares iso4217:USD shares false 0001649904 8-K 2024-02-29 RHYTHM PHARMACEUTICALS, INC. DE 001-38223 46-2159271 222 Berkeley Street 12th Floor Boston MA 02116 857 264-4280 false false false false Common Stock, $0.001 par value per share RYTM NASDAQ false